Introduction
============

Breast cancer is the most common cancer in women, both in terms of incidence and mortality.[@b1-ijn-6-2265] Understanding its biological behavior and identifying objective prognosticators and biologic targets could help improve the outcome. The epidermal growth factor receptor (EGFR) is a member of the ErbB receptor family and is a new therapeutic target in solid tumors.[@b2-ijn-6-2265] To date, four members of the ErbB receptor family have been identified, including EGFR (HER1/ErbB-1), HER2 (ErbB-2/neu), HER3 (ErbB-3), and HER4 (ErbB-4). These ErbB receptors are widely expressed in several mammalian tissues and cell types, particularly those of epithelial, mesenchymal, and neuronal origin. They participate actively in physiological functions, such as cell proliferation and differentiation, cell-- cell interaction, cytokine signaling and stress responses, and in oncological activities, such as cancer cell proliferation, survival, and metastasis.[@b2-ijn-6-2265],[@b3-ijn-6-2265] Structurally, EGFR is a transmembrane protein with an extracellular epidermal growth factor-binding domain, a transmembrane region, and an intracellular domain with ligand-activated tyrosine kinase activity. EGFR has been identified as a key cell surface receptor involved in a complex signaling network, with a binding capacity to various classes of agonists, including epidermal growth factor, transforming growth factor alpha, heparin-binding epidermal growth factor-like growth factor, amphiregulin, epiregulin, epigen, betacellulin, and neuregulin 2β.[@b4-ijn-6-2265] The clinical value of EGFR in breast cancer remains controversial.[@b5-ijn-6-2265]--[@b9-ijn-6-2265] Some researchers have demonstrated a significant negative impact of EGFR overexpression on both relapse-free survival and overall survival,[@b5-ijn-6-2265]--[@b7-ijn-6-2265] while others have failed to establish such a link.[@b8-ijn-6-2265],[@b9-ijn-6-2265] The causes for discrepancies among these studies may not only be due to differences in sample size and durations of follow-up, but also due to use of differing analytical procedures with different cutoff levels. Currently, the most commonly used method to detect EGFR in breast cancer specimens is immunohistochemistry. This conventional staining method may not be appropriate to investigate the role of EGFR in breast cancer because of its technical shortcomings, such as being prone to interfering factors, unstable sensitivity, high discrepancy between laboratories, and subjective interpretation.[@b9-ijn-6-2265],[@b10-ijn-6-2265]

Quantum dots are semiconductor nanocrystals with a core/shell structure and a large spectral band gap, with unique photodynamic properties such as size-tunable symmetric emission bands, strong light absorbance, high fluorescent intensity, and high photostability.[@b11-ijn-6-2265] Quantum dot fluorescence can be separated from background autofluorescence in biological specimens, including cells and tissues.[@b12-ijn-6-2265] These properties facilitate integration of nanotechnology and biology, contributing to major advances in medical diagnostics, targeted therapeutics, and cellular and molecular biological studies.[@b11-ijn-6-2265]--[@b13-ijn-6-2265] Notably, bioconjugation of quantum dots with functional molecules like antigens and antibodies offers a new pathway to enhanced sensing and imaging technologies.[@b13-ijn-6-2265] Our previous study of molecular targeted imaging of cancer cells and molecules[@b14-ijn-6-2265]--[@b16-ijn-6-2265] has demonstrated the advantages of quantum dot-based molecular pathology, such as higher fluorescent efficiency over organic fluorescent dyes, better signal clarity, and a higher sensitivity and accuracy compared with conventional immunohistochemistry techniques. Therefore, quantum dot-based nanotechnology opens a new window to gain better insights into tumor biology. This study was undertaken to investigate the prognostic value of EGFR in breast cancer using quantum dot-based quantitative nanotechnology and spectrum analysis.

Materials and methods
=====================

Patients and specimens
----------------------

Complete information on the clinicopathological characteristics of patients and fabrication of tissue microarrays has been detailed in our previous study.[@b16-ijn-6-2265] Briefly, tumor specimens from 240 patients aged 29--78 (median 48) years with invasive breast cancer were collected from Hubei Cancer Hospital, Wuhan, China, from January 2002 to December 2006. Two tissue cores representing two different invasive areas were obtained for each specimen, giving 480 cores for 240 specimens. Seven tissue microarray blocks were constructed, six containing 70 cores and one containing 60 cores. Consecutive sections (4 μm in thickness) of the tissue microarray blocks were cut to make tissue microarray slides. Major pathological parameters were available, including tumor size, location and number, lymph node status, histological grade, hormone receptor status, and HER2 status, as determined by conventional immunohistochemistry. All the patients were on a regular follow-up schedule. Written informed consent was obtained from the patients, and the study protocol was approved by the ethics committee.

The primary end point was recurrence-free survival, defined as the time interval from breast cancer surgery to the first evidence of recurrence (local, regional, or distant).[@b16-ijn-6-2265] If without recurrence, patients were censored on the last follow-up. In this study, we only selected the five-year data for analysis.

EGFR testing
------------

The antibodies were purchased from Zhongshan Golden Bridge Biotechnology Co Ltd, Beijing, China. The primary antibody was rabbit antihuman monoclonal antibody against EGFR (clone SP9, 1:120 dilution) and the control group antibody was rabbit IgG (1:120 dilution). Biotinylated goat antirabbit IgG (1:400 dilution) was the secondary antibody. The three-step avidin-biotin-horseradish peroxidase complex method (ABC, MaiXin Bio Co Ltd, Fuzhou, China) was used for immunohistochemistry. A quantum dot-conjugated streptavidin probe (1:200 dilution) with a 605 nm emission wavelength was obtained from Wuhan Jiayuan Quantum Dots Co Ltd, Wuhan, China.

Quantum dot-immunohistochemistry was similar to conventional immunohistochemistry, with the major procedures described in our previous study,[@b14-ijn-6-2265]--[@b16-ijn-6-2265] including the following brief steps: deparaffinizing → antigen retrieval → blocking → primary antibody (rabbit IgG for control group) → washing → blocking → biotinylated secondary antibody → washing → blocking → quantum dot-conjugated streptavidin probes → washing → mounting and observation.

This study was divided into two parts, ie, a feasibility study and a confirmation study. In the feasibility study, 65 specimens randomly selected from 240 breast cancer specimens were detected by both conventional immunohistochemistry and quantum dot-immunohistochemistry. One hundred tumor cells from five representative fields of each specimen at high magnification (400×) were counted for EGFR-positive cells. The EGFR positivity rates detected by quantum dot-immunohistochemistry and immunohistochemistry staining were compared. In the confirmation study, quantum dot-based immunofluorescent imaging of EGFR was conducted using the 605 nm quantum dot-conjugated streptavidin probe on the abovementioned tissue microarray slides. The slides were examined under an Olympus BX51 fluorescence microscope equipped with an Olympus DP72 camera (Olympus Optical Co Ltd, Tokyo, Japan) and a multispectral imaging Nuance system (Cambridge Research and Instrumentation Inc, Woburn, MA). The 605 quantum dots were excited by blue light (excitation wavelength 450--480 nm). Images of the quantum dots were captured using a DP72 camera. The spectral cube for each core of tissue microarray containing complete spectral information at 10 nm wavelength intervals from 520 to 680 nm was collected by the Nuance system. All the cubes were captured under the same conditions at low magnifications (40×), because this technique could obtain the entire images for each core, making it more accurate and representative in the tumor marker assay. Quantum dot fluorescence signal information for every core was analyzed by the analysis software package (Nuance version 2.8) within the Nuance system.

EGFR fluorescence signals and distribution area in the tumor were calculated numerically based on spectral unmixing. The distribution area of internal cytokeratin imaging was measured using the same method and conditions as in our previous study,[@b16-ijn-6-2265] and defined as the total area of tumor cells. The ratio of EGFR distribution area to cytokeratin area was calculated and defined as a percentage of EGFR-positive area. The EGFR area was calculated by the following equation:
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The acquired total fluorescence areas of EGFR were defined as the sum of EGFR fluorescence areas on the two cores of tissue microarray.

Statistical analysis
--------------------

The Spearman's rho correlation, consistency (κ) check and Chi-square test were used to compare the results for quantum dot-immunohistochemistry and immunohistochemistry. Differences in EGFR areas were assessed using the Mann-- Whitney U test or Kruskal--Wallis H test. Receiver-operating characteristic (ROC) curve analysis was conducted to evaluate the predictive value of the EGFR area for five-year recurrence-free survival. The optimal point with the highest sum value of sensitivity and specificity was defined as the cutoff. The Kaplan--Meier method was used to assess for differences in five-year recurrence-free survival. A multivariate Cox regression model was used to select independent predictors of five-year recurrence-free survival. Statistical analyses were performed using SPSS 13.0 software (SPSS Inc, Chicago, IL). Two-tailed *P* \< 0.05 was considered to be statistically significant.

Results
=======

EGFR expression in feasibility study
------------------------------------

In the feasibility study, EGFR expression was observed on the same location on the membranes and in the cytoplasm by quantum dot-immunohistochemistry ([Figure 1A](#f1-ijn-6-2265){ref-type="fig"}) and immunohistochemistry ([Figure 1B](#f1-ijn-6-2265){ref-type="fig"}). The isotype control group (rabbit IgG) did not show any positive expression on breast cancer cells ([Figure 1C and D](#f1-ijn-6-2265){ref-type="fig"}). EGFR staining rates detected by quantum dot-immunohistochemistry and immunohistochemistry were 0%--85% and 0%--82%, respectively. Median EGFR staining rates by quantum dot-immunohistochemistry and immunohistochemistry were 15% (25%--75% interquartile range, 8%--38.5%) and 13% (25%--75% interquartile range, 5%--35.5%), respectively. Spearman's rho correlation analysis showed that the correlation coefficient of EGFR staining rates by the two methods was 0.914. According to the EGFR PharmaDx Interpretation Manual,[@b17-ijn-6-2265] with a EGFR staining rate of 30% set as cutoff, 20 (30.8%) cases were positive by quantum dot- immunohistochemistry and 19 (29.2%) cases were positive by immunohistochemistry (*P* = 0.848). Of 65 cases, 19 cases were concurrently positive by two methods (κ = 0.848, consistency check). Both methods revealed the same antigen distribution and measurement consistency. These results suggest that quantum dot-immunohistochemistry had performance equal to that of conventional immunohistochemistry.

EGFR area in 240 cases
----------------------

Among 240 breast cancer specimens, EGFR expression was observed in 235 tumors ([Figure 2A, E, and G](#f2-ijn-6-2265){ref-type="fig"}), and five tumors did not show any EGFR signal ([Figure 2B](#f2-ijn-6-2265){ref-type="fig"}). Quantum dot signals of EGFR were obtained from cubes by spectral unmixing ([Figure 2C, D, and F](#f2-ijn-6-2265){ref-type="fig"}). The control group showed no EGFR expression ([Figure 2H](#f2-ijn-6-2265){ref-type="fig"}). The EGFR total fluorescence areas of the 235 samples ranged from 171 to 176,629. The median EGFR area of all the breast cancer patients was 33.08 (25%--75% interquartile range, 11.79--59.77), after adjustment for the area of cytokeratin (internal control).

Relationship between EGFR area and clinicopathological features
---------------------------------------------------------------

The association between EGFR area and major clinicopathological features, including age, tumor size, lymph node status, tumor grade, hormone receptor status, and HER2 status was evaluated. EGFR area was significantly correlated with lymph node status, hormone receptor status, HER2 status, and tumor grading. No significant relationship was found between EGFR area and the other clinicopathological features ([Table 1](#t1-ijn-6-2265){ref-type="table"}).

ROC analysis of EGFR area by five-year recurrence-free survival
---------------------------------------------------------------

ROC analysis of EGFR area by five-year recurrence is shown in [Figure 3A](#f3-ijn-6-2265){ref-type="fig"}, which indicates that the quantum dot-based EGFR area could predict five-year recurrence. According to the optimal sensitivity and specificity of the ROC curve by five-year recurrence status, 30.51 were defined as the optimal cutoff for EGFR area, with sensitivity of 65.9% and specificity of 55%.

EGFR area and five-year recurrence-free survival
------------------------------------------------

In this study, the five-year recurrence rate was 37.9% (91/240), with 20 local recurrences and 71 distant recurrences. Based on the cutoff value of 30.51 for EGFR fluorescence area, the 240 breast cancer tumors were classified into two subgroups, ie, tumors with a small EGFR area (\<30.51, n = 113) and those with a large EGFR area (≥30.51, n = 127). The five-year recurrence rate was 47.2% in patients with a large EGFR area, and 27.4% in those with a small EGFR area (*P* = 0.002). The five-year recurrence-free survival of the two groups showed a significant difference (*P* = 0.0015, log-rank test, [Figure 3B](#f3-ijn-6-2265){ref-type="fig"}).

Univariate analysis indicated that lymph node status, tumor grade, tumor size, HER2 status, EGFR area, and hormone receptor status had significant correlations with five-year recurrence-free survival (all *P* \< 0.05, [Table 2](#t2-ijn-6-2265){ref-type="table"}). However, among all the above factors, multivariate analysis using a Cox regression model revealed that only lymph node status, tumor size, tumor grade, and HER2 status were independent prognosticators, whereas the other factors, including EGFR area, were not in the equation.

The 240 patients were further classified into subgroups according to lymph node status, tumor size, HER2 status, and hormone receptor status. Univariate analysis and multivariate analysis indicated that EGFR area was an independent prognosticator in the lymph node-positive and HER2-positive subgroups ([Table 2](#t2-ijn-6-2265){ref-type="table"}), whereas in other subgroups, EGFR area did not enter into the equation of multivariate analysis.

Five-year recurrence rate and recurrence-free survival were investigated in the HER2 and lymph node subgroups. The differences in five-year recurrence rate and recurrence-free survival between patients with a large EGFR area and a small EGFR area in the HER2-negative and lymph node-negative subgroups did not reach statistical significance (both *P* \> 0.05, [Figure 4A and B](#f4-ijn-6-2265){ref-type="fig"}).

In the HER2-positive subgroup, the five-year recurrence rate was 55.7% (39/70) in patients with a large EGFR area and 34.0% (18/53) in those with a small area (*P* = 0.017). The median five-year recurrence-free survival in patients with a large EGFR area was 41.0 months (95% confidence interval \[CI\] 16.4--65.6 months), but the median five-year recurrence-free survival in those with small EGFR area was not reached yet (*P* = 0.0098, log-rank test, [Figure 4C](#f4-ijn-6-2265){ref-type="fig"}). In the lymph node-positive subgroup, the five-year recurrence rate was 65.8% (52/79) in patients with a large EGFR area and 42.3% (22/52) in those with a small EGFR area (*P* = 0.008). The median five-year recurrence-free survival was 34.0 months (95% CI 19.9--28.1) in patients with a large EGFR area, but was not reached in those with a small EGFR area (*P* = 0.0079, log-rank, [Figure 4D](#f4-ijn-6-2265){ref-type="fig"}).

Discussion
==========

In this study, quantum dot-immunohistochemistry showed good correlation and consistency with conventional immunohistochemistry in detecting EGFR, and better image quality and sensitivity than conventional immunohistochemistry in detecting biomarkers, as previously reported.[@b14-ijn-6-2265] Taking advantage of the optical properties of quantum dots, which overcome the limitations associated with tissue autofluorescence, allow accurate determination of biomarkers, and quantify the biomarkers because of sharper and more photostable fluorescent signals of quantum dots than organic dyes,[@b11-ijn-6-2265]--[@b13-ijn-6-2265] we quantified the expression of EGFR in breast cancer specimens using a quantum dot-based immunofluorescence probe. From a new perspective, ie, the EGFR fluorescence area, we investigated the prognostic value of EGFR in breast cancer. Patients with a large EGFR area demonstrated a significantly higher five-year recurrence rate and worse recurrence-free survival. It was a prognostic predictor of five-year recurrence-free survival for the entire study population in univariate analysis, but not in multivariate analysis. However, in the HER2-positive and lymph node-positive subgroups, EGFR area was an independent prognostic predictor both in univariate analysis and multivariate analysis.

The prognostic significance of EGFR in breast cancer has been investigated for over 20 years, yet no agreement has been reached. Sainsbury et al[@b5-ijn-6-2265] investigated 139 patients with breast cancer and found that recurrence-free survival and overall survival were significantly worse for patients with EGFR-positive tumors compared with EGFR-negative tumors, that EGFR was the most important variable in predicting recurrence-free survival and overall survival in lymph node-negative patients, and that this was the second most important variable in lymph node-positive patients. However, Ferrero et al[@b8-ijn-6-2265] investigated 780 consecutive breast cancer patients using a specific ligand-binding assay and found that there was no link between tumor size, grade, node status, and EGFR tumor levels. There was a constant and significant decrease in EGFR tumor levels according to patient age, and a significant inverse relationship between estrogen receptor status and EGFR. Tsutsui et al[@b9-ijn-6-2265] investigated 1029 patients with primary breast cancer by immunohistochemistry and found that EGFR was an independent prognostic factor for recurrence-free survival and overall survival in all patients, but the value of EGFR was somewhat insufficient to achieve statistical significance for both recurrence-free survival and overall survival in the subgroups according to nodal status. These confusing and even contradictory findings justify the need to re-evaluate EGFR using other molecular methods in different patient populations.

With the recent advances in biomedical science, targeted therapies and personalized medicine hold the future in clinical practice. EGFR has been studied from different perspectives and has been considered as a new therapeutic target in solid tumors. Cetuximab, gefitinib, erlotinib, and lapatinib[@b17-ijn-6-2265]--[@b22-ijn-6-2265] are agents targeting the EGFR pathway, and have been approved for the treatment of advanced colorectal cancer, squamous cell carcinoma of the head and neck, advanced non-small cell lung cancer, pancreatic cancer, and breast cancer,[@b23-ijn-6-2265] which has led investigators to restudy EGFR from different perspectives.[@b24-ijn-6-2265]

In the ErbB family, HER2 is the most extensively studied member, and its overexpression is closely correlated with aggressive behavior and poor prognosis of breast cancer. The relationship between EGFR and HER2 in breast cancer has been extensively investigated. Recently, McIntyre et al[@b25-ijn-6-2265] investigated all receptors and ligands in the ErbB family using immunohistochemistry and found that the heterogeneity in expression of receptor and ligands was unexpectedly high, with HER2 ranking first and EGFR ranking second. Yonemori et al[@b26-ijn-6-2265] investigated the immunohistochemistry expression of EGFR, HER3, and HER4 in HER2-positive patients with breast cancer treated with trastuzumab-containing neoadjuvant chemotherapy, and found that only EGFR was a negative prognosticator of pathologic complete response in this HER2-positive population. With regard to the mechanism, one study reported that both EGFR and HER2 act synergistically to cause aberrant tumor growth, leading to early onset of metastasis and death.[@b27-ijn-6-2265] Overexpression of HER2 can potentiate EGFR signaling and contribute to EGFR-mediated transformation and tumor progression.[@b28-ijn-6-2265] Further, HER2/ EGFR heterodimers showed ineffective endocytosis and destruction of ligand-bound EGFR, in contrast with EGFR homodimers.[@b29-ijn-6-2265] Breast cancer with coexpression of EGFR and HER2 has been shown to have the worst prognosis, whereas the prognostic value of HER2 was stronger than that of EGFR in breast cancer.[@b30-ijn-6-2265] In accordance with these reports, our study confirmed that HER2 was an independent prognosticator of breast cancer. EGFR and HER2 had additive adverse effects on prognosis. Patients with both positive HER2 and a large EGFR area had worse recurrence-free survival, and a large EGFR area significantly increased five-year recurrence rate by 21.7% compared with a small EGFR area. Therefore, we suggest that simultaneous detection of HER2 and EGFR could improve the predictive value and enable better treatment decisions. Quantum dot-based concurrent labeling technology provides such potential.[@b31-ijn-6-2265]

Lymph node status is an important prognostic predictor of breast cancer. We observed that the EGFR area was significantly higher in our lymph node-positive subgroup than in our lymph node-negative subgroup. In the lymph node-positive subgroup, a large EGFR area significantly increased five-year recurrence rate by 23.5% comparing with a small EGFR area. In patients with simultaneous lymph node positivity and a large EGFR area, the median five-year recurrence-free survival was only 34.0 months, which implies that EGFR detection was more meaningful in patients with lymph node-positive breast cancer.

A couple of studies have reported a significant inverse relationship between EGFR and hormone receptor status.[@b5-ijn-6-2265],[@b6-ijn-6-2265],[@b8-ijn-6-2265] Consistent with these reports, we also observed an inverse relationship between EGFR area and hormone receptor status, and the EGFR area was significantly higher in the hormone receptor-negative group than in the hormone receptor-positive group.

This study has several limitations. First, it was a retrospective study using a nonrandomized database. Second, it included only 240 patients with breast cancer, and the median follow-up was only five years, so the results may have been more accurate with a larger sample size and longer follow up. Third, the treatment was not controlled, and we assumed that all 240 patients with breast cancer received optimal treatment after surgery, which might have introduced some bias in the results. Nevertheless, quantum dot-based nanotechnology provides a new insight into this elusive biomarker.

In conclusion, quantum dot-immunohistochemistry demonstrated a performance at least equivalent to that of immunohistochemistry in detecting EGFR in breast cancer specimens. Quantitative analysis with quantum dot- based technology indicated that EGFR area has a negative prognostic value in patients with HER2-positive and lymph node-positive breast cancer.
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![EGFR expression on breast cancer cells by quantum dot-immunohistochemistry and immunohistochemistry. EGFR-positive expression on breast cancer cells imaged under Olympus DP72 camera (400×) by quantum dot-immunohistochemistry (**A**) and immunohistochemistry (**B**), control group (rabbit IgG) showed no any positive expression on breast cancer cells by quantum dot-immunohistochemistry (**C**), and immunohistochemistry (**D**). Scale bar: 25 μm for (**A**, **B**, **C**, and **D**).\
**Abbreviation:** EGFR, epidermal growth factor receptor.](ijn-6-2265f1){#f1-ijn-6-2265}

![EGFR determination and quantitative analysis. EGFR positive expression (**A**) and EGFR-negative expression (**B**) imaged under DP72 camera (40×); EGFR signal distribution (**C**) and EGFR signal locating (**D**) in the core (40×) unmixed by the Nuance multispectral imaging system; EGFR-positive expression imaged under DP72 camera (200×) (**E**), EGFR signal analysis by Nuance multispectral imaging systems (**F**), EGFR positive expression (**G**) and negative control group (**H**) imaged under DP72 camera (400×). Scale bar: 250 μm for (**A**--**D**), 50 μm for (**E**), 25 μm for (**G** and **H**).\
**Abbreviation:** EGFR, epidermal growth factor receptor.](ijn-6-2265f2){#f2-ijn-6-2265}

![Receiver-operating characteristic analysis of EGFR area by five-year recurrent status of 240 cases (**A**) and the five-year recurrence-free survival of patients with different EGFR area (**B**).\
**Abbreviation:** EGFR, epidermal growth factor receptor.](ijn-6-2265f3){#f3-ijn-6-2265}

![The EGFR area and five-year recurrence-free survival in HER2 and lymph node subgroups.\
**Abbreviations:** EGFR, epidermal growth factor receptor; LN, lymph node.](ijn-6-2265f4){#f4-ijn-6-2265}

###### 

Main clinicopathological features and EGFR area of 240 patients with breast cancer

  Items               n (%)        EGFR area, median (IQR)   *P* value
  ------------------- ------------ ------------------------- -------------------------------------------------
  Age (years)                                                
   ≤50                149 (62.1)   32.28 (11.91, 59.09)      0.927[a](#tfn1-ijn-6-2265){ref-type="table-fn"}
   \>50               91 (37.9)    34.82 (11.72, 60.76)      
  Tumor size (cm)                                            
   T1 (T ≤ 2)         35 (14.6)    24.46 (4.71, 55.23)       0.102[b](#tfn2-ijn-6-2265){ref-type="table-fn"}
   T2 (2 \< T ≤ 5)    162 (67.5)   30.90 (7.57, 63.49)       
   T3 (T \> 5)        43 (17.9)    41.33 (27.50, 59.94)      
  Lymph node status                                          
   Positive           131 (54.6)   37.81 (15.43, 65.90)      0.009[a](#tfn1-ijn-6-2265){ref-type="table-fn"}
   Negative           109 (45.4)   24.04 (5.29, 55.31)       
  Tumor grade                                                
   Grade 1            40 (16.7)    29.70 (9.12, 59.35)       0.031[b](#tfn2-ijn-6-2265){ref-type="table-fn"}
   Grade 2            141 (58.8)   26.16 (6.18, 58.84)       
   Grade 3            59 (24.6)    45.31 (27.50, 62.45)      
  HR status                                                  
   Positive           152 (63.3)   29.28 (6.74, 58.03)       0.049[a](#tfn1-ijn-6-2265){ref-type="table-fn"}
   Negative           88 (36.7)    44.02 (14.47, 65.73)      
  HER2 status                                                
   Positive           123 (51.3)   46.61 (17.42, 66.35)      0.040[a](#tfn1-ijn-6-2265){ref-type="table-fn"}
   Negative           117 (48.7)   29.04 (9.41, 58.59)       

**Notes:** Mann--Whitney U test;

Kruskal--Wallis H test.

**Abbreviations:** EGFR, epidermal growth factor receptor; HR, hormone receptor; IQR, interquartile range.

###### 

Factors correlated with five-year recurrence-free survival of patients with breast cancer

  Patient group                            Univariate analysis   Multivariate analysis                                                             
  ---------------------------------------- --------------------- ----------------------- ------- ------- -------- -------- ------- ------- ------- --------
  Total cases (n = 240)                                                                                                                            
   Age                                     0.204                 0.652                   1.102   0.724   1.677    NE       NE      NE      NE      NE
   Grade                                   61.983                0.000                   4.439   3.063   6.433    30.419   0.000   3.074   2.062   6.045
   Lymph node status                       35.862                0.000                   5.035   2.966   8.545    20.555   0.000   3.512   2.040   6.323
   Tumor size                              24.190                0.000                   2.542   1.753   3.686    5.283    0.022   1.547   1.066   2.246
   HER2 status                             18.255                0.000                   2.603   1.678   4.038    5.034    0.025   1.218   1.025   1.448
   HR status                               12.799                0.000                   0.472   0.313   0.712    NE       NE      NE      NE      NE
   EGFR area                               9.576                 0.002                   1.984   1.286   3.063    NE       NE      NE      NE      NE
  Lymph node-positive subgroup (n = 131)                                                                                                           
   Age                                     0.005                 0.946                   1.016   0.639   1.616    NE       NE      NE      NE      NE
   Grade                                   23.691                0.000                   2.879   1.888   4.447    16.688   0.000   2.428   1.586   3.716
   Tumor size                              10.134                0.001                   1.900   1.280   2.820    NE       NE      NE      NE      NE
   HER2 status                             25.065                0.000                   3.367   2.093   5.416    18.599   0.000   2.897   1.787   4.699
   HR status                               20.782                0.000                   0.342   0.216   0.543    NE       NE      NE      NE      NE
   EGFR area                               6.654                 0.010                   1.930   1.171   3.182    5.174    0.023   1.789   1.084   2.953
  HER2-positive subgroup (n = 123)                                                                                                                 
   Age                                     0.802                 0.371                   1.274   0.750   2.162    NE       NE      NE      NE      NE
   Grade                                   34.649                0.000                   4.256   2.627   6.893    13.277   0.000   2.507   1.529   4.110
   Tumor size                              6.296                 0.011                   1.900   1.155   3.125    NE       NE      NE      NE      NE
   Lymph node status                       27.219                0.000                   9.624   4.111   22.532   16.738   0.000   6.316   2.612   15.272
   HR status                               7.501                 0.006                   0.474   0.277   0.809    NE       NE      NE      NE      NE
   EGFR area                               6.269                 0.012                   2.044   1.168   3.578    4.495    0.034   1.843   1.047   3.245

**Abbreviations:** RR, relative risk; NE, not in the equation; HR, hormone receptor; EGFR, epidermal growth factor receptor; CI, confidence interval.
